SPONSOR
Fred Hutchinson Cancer Center
Total Trials
11
Recruiting
11
Phases
Phase 2
Conditions studied: Chronic Graft Versus Host DiseaseAcute Leukemia of Ambiguous LineageAcute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic SyndromeAcute Graft Versus Host DiseaseHematopoietic and Lymphatic System NeoplasmCastration-Sensitive Prostate AdenocarcinomaMetastatic Castration-Sensitive Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8
Fred Hutchinson Cancer Center is a clinical research sponsor with 11 registered studies on ClinicalTrials.gov, of which 11 are actively recruiting participants. Research covers conditions including Chronic Graft Versus Host Disease, Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia.
The trial portfolio spans Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Fred Hutchinson Cancer Center
How many clinical trials has Fred Hutchinson Cancer Center sponsored?
ClinicalMetric currently tracks 11 clinical trials sponsored by Fred Hutchinson Cancer Center, of which 11 are actively recruiting participants. These trials cover conditions including Chronic Graft Versus Host Disease, Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Fred Hutchinson Cancer Center research focus on?
Fred Hutchinson Cancer Center clinical trials span Chronic Graft Versus Host Disease, Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, and additional conditions. The research pipeline includes Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Fred Hutchinson Cancer Center clinical trial?
To participate in a Fred Hutchinson Cancer Center trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Fred Hutchinson Cancer Center trials with current recruitment status updated daily.
Clinical Trials by Fred Hutchinson Cancer Center
NCT07011810 Phase 2
Recruiting
Axatilimab for Sclerotic Chronic Graft-versus-Host Disease
Chronic Graft Versus Host Disease
NCT07046078 Phase 2
Recruiting
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
Acute Leukemia of Ambiguous Lineage
NCT07535008
Recruiting
Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease
Chronic Graft Versus Host Disease
NCT07466498 Phase 2
Recruiting
Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial
Castration-Sensitive Prostate Adenocarcinoma
NCT07645378
Recruiting
Feasibility Study Comparing One vs Two Probes for Thermal Ablation Among Cervical Cancer Screen Positive WLWH in C1001P-CS9 South Africa
HIV (Human Immunodeficiency Virus)
NCT06934369
Recruiting
Improving Engagement in HIV and Cancer Care in Zimbabwe
Cancer
NCT07228624 Phase 2
Recruiting
Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
Myelodysplastic/Myeloproliferative Neoplasm
NCT07731880
Recruiting
Influencing Next-Generation Oncologic Outcomes Through Rapid Integration of Functional Precision Medicine (NOORI): A Feasibility Study of SmartMatch in Rare Gynecologic Cancers
Malignant Female Reproductive System Neoplasm
NCT03980769 Phase 2
Recruiting
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders
Non-Neoplastic Hematopoietic and Lymphoid Cell Disorder
NCT07209371 Phase 2
Recruiting
Rifaximin Versus No Intervention for the Treatment of IgG/IgA (Non-IgM) Monoclonal Gammopathy of Undetermined Significance
IgA Monoclonal Gammopathy of Undetermined Significance
NCT04829136
Recruiting
Sustained Oral Fiber Supplementation for Patients Undergoing Treatment for Hematological Malignancies
Hematopoietic and Lymphatic System Neoplasm
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology